CD14 and COVID-19: It is consistent with a previous report indicating that in symptomatic COVID-19 patients the percentage of CD14+/HLA-DR+ monocytes increase in the PBMCs while the CD14lowCD16+ inflammatory monocytes decrease as they leave the bloodstream and homing tissues (70).